Europe
Kadans expands its presence in the United Kingdom by adding its second research hub in the country to its Pan-European science park portfolio.
HOOKIPA Pharma Inc. reported recent clinical progress highlights and financial results for the second quarter ended June 30, 2019.
Insilico Biotechnology AG and the Laboratory of Systems Theory and Automatic Control at the Institute for Automation Engineering of the Otto von Guericke University Magdeburg started a joint project on model predictive control for the production of monoclonal antibodies in mammalian cell culture processes using Insilico’s Digital Twins.
S3 Process, an OEM specialising in process equipment for the pharmaceutical industry, is using BioPure BioClamp® and BioPure silicone gasket technology on its new PuroVaso® containers, for the effective handling of powders and tablets in life science applications.
Biopharma companies from across the globe provide updates on their pipeline and business.
Adrenomed AG, the vascular integrity company, announced its participation at four upcoming conferences in Europe.
Pulmocide Ltd is pleased to announce that in vitro data published in the Journal of Antimicrobial Chemotherapy highlight the potential of its novel antifungal candidate PC945 in the treatment of Candida auris.
Pharming Group N.V. announced it has entered into a development collaboration and license agreement with Novartis to develop and commercialize CDZ173, a small molecule phosphoinositide 3-kinase delta (PI3Kẟ) inhibitor being developed by Novartis to treat patients with Activated Phosphoinositide 3-kinase Delta Syndrome.
Pharming paid Novartis an upfront fee of $20 million for the asset, a small molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class IA PI3K with immune-modulating and potentially anti-neoplastic activities.
Jack Bailey, head of the company’s U.S. pharmaceuticals business is stepping down at the end of the year.
PRESS RELEASES